Biotek-snakken — Juli 2022
-
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will host a virtual research forum in which it will unveil the next product candidate, discuss immunostimulatory ADCs (iADCs) as a novel modality, and highlight recent enhancement to its cell-free manufacturing platform. Webcast de
Yahoo Finance (finance.yahoo.com)
-
ANALYSIS-Bruised investors seek shelter in U.S. healthcare stocks https://www.proinvestor.com/investornyt/849645/analysis-bruised-investors-seek-shelter-in-us-healthcare-stocks
-
Biotek i positiv trend. Sidste efterår begyndte grønne aktier og vækstaktier at ryge ned i kælderen kursmæssigt. Biotekaktierne fik også stryg. Men i maj begyndte nogle amerikanske biotekvirksomheder at lave bundvendinger, og siden er det begyndt at gå rigtig godt for nogle af de biotek-darlings, der er på ProInvestor.com. https://www.proinvestor.com/boards/104440
-
Godmorgen,
-
Topchef i dansk-svensk biotekselskab fratræder - fremtiden usikker https://www.proinvestor.com/investornyt/850759/topchef-i-dansk-svensk-biotekselskab-fratraeder-fremtiden-usikker
-
Friday Sector Laggards: Biotechnology, Precious Metals https://www.proinvestor.com/investornyt/851087/friday-sector-laggards-biotechnology-precious-metals
-
-
Regnskab fra XBrane…ser fint ud, der brændes mindre penge af
https://xbrane.com/wp-content/uploads/2022/07/Xbrane-Report-Q2-ENG-Final.pdf -
Præsentation kl 10… https://edge.media-server.com/mmc/p/ao32axjq
-
Fra CC: hvis XBrane skulle få brug for mere cash (afhænger af hvornår Xlucane kommer på markedet) vil det ske gennem royalty af salget og ikke flere emissioner. Det begynder at se rigtig godt ud
-
Xbrane Biopharma Q2’22: Xlucane
Launch Anticipated to Q1’23
Research Note Friday July 22
Redeye comments on Xbrane Biopharma’s Q2 2022 report, which despite the recent setback, leaves us feeling encouraged ahead of the European launch of Xlucane, anticipated in Q1 2023. https://www.redeye.se/research/849301/xbrane-biopharma-q222-xlucane-launch-anticipated-to-q123?utm_source=note&utm_medium=email -
Især bemærkningen om evt adgang til finansiering gennem non-dilutive finansiering ser godt ud
With SEK 250m cash on the balance sheet at the end of the second quarter, there should be no financing need in the coming twelve months. With current prospects, the company has financial flexibility and could likely access non-dilutive financing as options if required
. -
What's the best stock to buy right now? Our healthcare roundtable nominates our three favorites https://www.proinvestor.com/investornyt/854766/2022-roundtable-our-favorite-picks-right-now
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind